Novavax Enters Amendment to Advanced Purchase Agreement with Commonwealth of Australia
| NVAX Stock | USD 8.64 0.06 0.69% |
Slightly above 61% of Novavax's investor base is looking to short. The analysis of the overall investor sentiment regarding Novavax suggests that many traders are alarmed. Novavax's investing sentiment can be driven by a variety of factors including economic data, Novavax's earnings reports, geopolitical events, and overall market trends.
Novavax |
Novavax, Inc. has recently disclosed an Amendment to the Advanced Purchase Agreement with the Commonwealth of Australia as Represented by the Department of Health and Aged Care. The Amendment, marked as Amendment 5, was entered into on December 12, 2024. Under this Amendment, Novavax acknowledged the cancellation by the Commonwealth of
Read at thelincolnianonline.com
 |
Novavax Fundamental Analysis
We analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Novavax is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Novavax Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Novavax stock to make a market-neutral strategy. Peer analysis of Novavax could also be used in its relative valuation, which is a method of valuing Novavax by comparing valuation metrics with similar companies.
Peers
Novavax Related Equities
| VXRT | Vaxart | 3.33 | ||||
| AZN | AstraZeneca PLC | 1.41 | ||||
| MRNA | Moderna | 0.51 | ||||
| BNTX | BioNTech | 0.38 | ||||
| INO | Inovio Pharmaceuticals | 2.72 |
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.